We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01623349
Recruitment Status : Active, not recruiting
First Posted : June 20, 2012
Last Update Posted : March 23, 2017
Sponsor:
Collaborators:
Information provided by (Responsible Party):

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : August 2017
  Estimated Study Completion Date : December 2017